Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + FOLFIRI in 2nd-line mCRC
NCT01298570Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2011
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Apr 2011; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01298570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298570.